Trends in Pharmacological Sciences
A renaissance in trace amines inspired by a novel GPCR family
Section snippets
Trace amines find their receptors
The classical biogenic amines [serotonin (5-HT), noradrenaline, adrenaline, dopamine and histamine] have important roles as neurotransmitters in the central and peripheral nervous systems [1]. Their synthesis and storage, in addition to their degradation and reuptake after release, are tightly regulated, and an imbalance in the levels of biogenic amines is known to be responsible for altered brain function in many pathological conditions 2, 3, 4, 5. A second class of endogenous amine compounds,
Molecular properties of trace amine-associated receptors
All mammalian TAARs analyzed to date share several molecular properties [15]. All except one TAAR gene [TAAR2 (GPR58)] are single-exon encoded, locate to a narrow region of ∼100–200 kb of a single chromosome and have coding sequences of ∼1 kb in length. The total number of genes and the proportion of intact genes compared with the proportion of pseudogenes differ substantially between species: there are 19 (including 2 pseudogenes) and 16 (including 1 pseudogene) TAAR genes in rat and mouse
Trace amine metabolism and pharmacology
TAs (β-PEA, p-tyramine, octopamine and tryptamine) are all primary amines generated directly by enzymatic decarboxylation of their respective precursor amino acids or, in the case of octopamine, via additional conversion by dopamine β-hydroxylase (DBH) (Figure 2). TAs are metabolized to biologically inactive degradation products predominantly via monoamine oxidase (MAO) with different selectivities for the MAO-A or MAO-B subtype. As a result of the rapid turnover rate of TAs, the endogenous
TAARs as potential drug targets for the treatment of psychiatric disorders
The dysregulation of TA levels has been linked to several diseases, which highlights the corresponding members of the TAAR family as potential targets for drug development. In this article, we focus on the relevance of TAs and their receptors to nervous system-related disorders, namely schizophrenia and depression; however, TAs have also been linked to other diseases such as migraine, attention deficit hyperactivity disorder, substance abuse and eating disorders 7, 8, 36.
Clinical studies report
Outlook and future perspectives
The identification of specific receptors has always been key to the understanding of the biological function and pharmacology of any transmitter-like biological compound, as the example of histamine illustrates well: when the importance of amine-mediated systems emerged in the 1960s, it was only after the identification of specific receptors that histamine was generally accepted as an established neurotransmitter 56, 57. Likewise, it is only the recent identification of TAARs, some of which
Acknowledgements
We would like to thank our colleagues M. Ebeling, N.A. Kratochwil, J-L. Moreau, H. Stalder, S. Kolczewski, E. Borroni, J.G. Wettstein, A.J. Sleight and D.K. Grandy for many stimulating discussions. We acknowledge the continued support by F. Hoffmann-La Roche.
References (60)
- et al.
Trace amine receptors as targets for novel therapeutics: legend, myth and fact
Curr. Opin. Pharmacol.
(2003) - et al.
A high-affinity [3H] tryptamine binding site in human brain
Prog. Brain Res.
(1995) Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor
Life Sci.
(1989)Trace amine associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors
Genomics
(2005)GPCR deorphanizations: the novel, the known and the unexpected transmitters
Trends Pharmacol. Sci.
(2005)- et al.
Tryptamine and 5-hydroxytryptamine: actions and interactions of cortical neurones in the rat
Life Sci.
(1980) Tryptamine modifies cortical neurone responses evoked by stimulation of nucleus raphe medianus
Brain Res. Bull.
(1982)Absence of 2-phenylethylamine binding after monoamine oxidase inhibition in rat brain
Eur. J. Pharmacol.
(1992)Specific [3H] beta-phenylethylamine binding sites in rat brain
Eur. J. Pharmacol.
(1982)- et al.
Characterization of [3H] tryptamine binding sites in brain
Eur. J. Pharmacol.
(1983)
Aromatic L-amino acid decarboxylase in the rat brain: immunocytochemical localization in neurons of the brain stem
Neuroscience
Peptide and trace amine orphan receptors: prospects for new therapeutic targets
Curr. Opin. Pharmacol.
Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees
Genomics
Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia
Am. J. Hum. Genet.
Schizophrenia
Lancet
The trace amines and their acidic metabolites in depression - an overview
Prog. Neuropsychopharmacol. Biol. Psychiatry
Decreased cerebrospinal fluid concentration of free phenylacetic acid in depressive illness
Clin. Chim. Acta
Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus
Neuroscience
A detailed mapping of histamine H1-receptors in guinea-pig central nervous system established by autoradiography with [125I] iodobolpyramine
Neuroscience
Neurotransmitters
Research and treatment approaches to depression
Nat. Rev. Neurosci.
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
Annu. Rev. Pharmacol. Toxicol.
Recent developments in the pharmacological treatment of Parkinson's disease
Expert Opin. Investig. Drugs
Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes
Nat. Rev. Neurosci.
Following the trace of elusive amines
Proc. Natl. Acad. Sci. U. S. A.
Autoradiographic localization of tryptamine binding sites in the rat and dog central nervous system
J. Neurosci.
Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding
J. Pharmacol. Exp. Ther.
Trace amines: identification of a family of mammalian G protein-coupled receptors
Proc. Natl. Acad. Sci. U. S. A.
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
Mol. Pharmacol.
Cited by (232)
TAAR1 as an emerging target for the treatment of psychiatric disorders
2024, Pharmacology and TherapeuticsTrace amine-associated receptor 1 and drug abuse
2022, Advances in PharmacologyCitation Excerpt :It was challenging to study TAAR1 initially because of the lack of expression at the plasma membrane in vitro as observed in microscopy images (Miller, 2011). Thus, many earlier studies of TAAR1 pharmacology required modifications to the receptor so as to increase its membrane expression (Bunzow et al., 2001; Lindemann & Hoener, 2005; Reese, Bunzow, Arttamangkul, Sonders, & Grandy, 2007; Wainscott et al., 2007). Moreover, it is shown that rhesus monkey TAAR1 interacts with monoamine transporters and thus provide an access by which TAAR1 ligands can enter the cytoplasm and bind to TAAR1.
Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review
2021, Neuroscience and Biobehavioral ReviewsCitation Excerpt :Downstream β-hydroxylated, N-, and O- methylated forms of these trace amines are now known to act on TAAR1, among other TAARs (Gainetdinov et al., 2018; Lindemann and Hoener, 2005). This is also true of both the monoamine neurotransmitters as well as their O- and N-methylated metabolites from the respective methyltransferases (Bunzow et al., 2001; Lindemann and Hoener, 2005; Sotnikova et al., 2010). Additional discoveries of active ligands further broadened the pharmacology of TAARs beyond compounds in the metabolic pathways of amino acids and classical neurotransmitters.
Current Landscape on Development of Phenylalanine and Toxicity of its Metabolites-A Review
2024, Current Drug Safety